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Abstract: The molecular chaperone Hsp90 is regulated by co-chaperones such as p50Cdc37, 
which recruits a wide selection of client protein kinases. Targeted disruption of the  
Hsp90-p50Cdc37 complex by protein–protein interaction (PPI) inhibitors has emerged as  
an alternative strategy to treat diseases characterized by aberrant Hsp90 activity. Using 
isothermal microcalorimetry, ELISA and GST-pull down assays we evaluated reported 
Hsp90 inhibitors and nucleotides for their ability to inhibit formation of the human  
Hsp90β-p50Cdc37 complex, reconstituted in vitro from full-length proteins. Hsp90 inhibitors, 
including the proposed PPI inhibitors gedunin and H2-gamendazole, did not affect the 
interaction of Hsp90 with p50Cdc37 in vitro. Phosphorylation of Hsp90 and p50Cdc37 by casein 
kinase 2 (CK2) did not alter the thermodynamic signature of complex formation. However, 
the phosphorylated complex was vulnerable to disruption by ADP (IC50 = 32 µM), while 
ATP, AMPPNP and Hsp90 inhibitors remained largely ineffective. The differential inhibitory 
activity of ADP suggests that phosphorylation by CK2 primes the complex for dissociation 
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in response to a drop in ATP/ADP levels. The approach applied herein provides robust assays 
for a comprehensive biochemical evaluation of potential effectors of the Hsp90-p50Cdc37 
complex, such as phosphorylation by a kinase or the interaction with small molecule ligands. 
Keywords: heat shock proteins; protein–protein interactions; protein phosphorylation; protein 
kinase; small molecule inhibitors 
 
1. Introduction 
The 90 kDa heat shock protein (Hsp90) is a highly conserved molecular chaperone that activates or 
protects client proteins in an ATP-dependent manner. The two cytosolic homologues of human Hsp90 
(α and β) have a sequence similarity of more than 85%, but little is known about their differences in 
function [1,2]. Hsp90 and its co-chaperones have been associated with various types of cancer [3–5], 
Alzheimer’s and other neurodegenerative diseases [6], viral diseases [7] and vascular diseases [8].  
The specificity of Hsp90 towards more than 300 different client proteins is controlled by a variety of  
co-chaperones, including p50Cdc37 [9]. p50Cdc37 is involved in the recruitment of more than 45 different 
kinases to Hsp90, resulting in their subsequent activation, and many of these client kinases have been 
implicated in oncogenic pathways [4]. Silencing of p50Cdc37 in human colon and breast cancer cell lines 
destabilizes many of these kinases in vivo, leading to decreased proliferation and increased sensitivity of 
these cell types to Hsp90 inhibitors [10]. 
During acute heat shock, the phosphorylation of Hsp90 significantly increases [11]. Several kinases 
are known to phosphorylate Hsp90, the most prominent of which are casein kinase II (CK2) [12] and 
Wee1 [13,14]. CK2 phosphorylates several serine and threonine residues in Hsp90 and in co-chaperone 
proteins such as p50Cdc37and p23, constituting an important but complex regulatory component of chaperone 
function in eukaryotic cells [15,16]. CK2 phosphorylates Hsp90β at multiple residues [12,15], affecting 
its ability to interact with client proteins such as Apaf-1 and AhR [17,18]. Among the residues 
phosphorylated by CK2 are Ser226 and Ser255, located at a distinctive charged linker region between 
the N-terminal and the middle domain of Hsp90, the structure and function of which is obscure. Deletion 
of this charged linker decreases the ability of Hsp90 proteins to function as chaperones in the cell [19,20]. 
Phosphorylation of p50Cdc37 at residue Ser13 by CK2 affects the recruitment of client kinases to the 
Hsp90-p50Cdc37 complex [21,22]. In addition to the phosphorylation by CK2 and Wee1, Hsp90 is also 
subject to phosphorylation by v-Src [23]. 
Several small molecule inhibitors of Hsp90 have been developed as potential therapeutic agents. 
NVP-AUY922 is currently in Phase II clinical trials for non-small cell lung cancer (NSCLC) [5,24,25], 
Ganetespib is in Phase III combination therapy trials with docetaxel for NSCLC, while Phase III  
trials with Retaspimycin (IPI-504) and Tanespimycin (17-AAG) have been terminated or halted 
(www.clinicaltrials.gov). The majority of reported and validated Hsp90 inhibitors exclusively target the 
ATP site of the N-terminal domain of Hsp90. However, the association of Hsp90 with co-chaperones 
has stimulated efforts towards the development of protein–protein interaction (PPI) inhibitors.  
Non-hydrolysable ATP analogues were reported to disrupt complex formation between Hsp90β and 
p50Cdc37, while ADP, geldanamycin, and the geldanamycin derivatives 17-AAG and 17-DMAG showed 
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no effect [26]. It was recently suggested that Hsp90 is a molecular target of the male contraceptive drug 
candidate H2-gamendazole (H2-GMZ) [27,28], and it was concluded that H2-GMZ shares a similar 
mode of action as the proposed PPI inhibitor gedunin by inhibiting formation of the Hsp90-p50Cdc37 
complex [29]. 
Here we evaluated the ability of reported Hsp90 inhibitors and nucleotides to disrupt the interaction 
of human full-length Hsp90β and p50Cdc37 using isothermal titration calorimetry (ITC), ELISA, and GST 
pull-down assays. We show that previously reported PPI inhibitors of the Hsp90-p50Cdc37 complex lack 
binding potential or inhibitory activity against the complex. Among the compounds tested only ADP 
effectively disrupted the complex, particularly upon phosphorylation by CK2.  
2. Results and Discussion 
2.1. In Vitro Reconstitution of the Human Hsp90β-p50Cdc37 Complex and Phosphorylation by CK2 
The ability of human p50Cdc37 to interact with human Hsp90 was assessed using full-length Hsp90β, 
a deletion mutant of Hsp90β (denoted ΔHsp90) which lacks the charged linker region residues 220–275, 
and the N-terminal domain of Hsp90β (denoted N-Hsp90). All proteins were purified to homogeneity, 
and size-exclusion chromatography confirmed that Hsp90 and p50Cdc37 eluted as dimeric proteins. 
Addition of p50Cdc37 to Hsp90β resulted in the formation of a stable complex with 1:1 stoichiometry as 
judged by SDS-PAGE (Figure 1A). Full-length Hsp90β is subject to phosphorylation by CK2 at residues 
Ser226 and Ser255 of the charged linker region [12], and p50Cdc37 is phosphorylated by CK2 at residue 
Ser13 [21]. In order to evaluate the effect of phosphorylation on the formation and stability of the  
Hsp90-p50Cdc37 complex, we produced recombinant human CK2α for the quantitative phosphorylation 
of both Hsp90 and p50Cdc37. Phosphorylation of Ser255 of Hsp90β and Ser13 of p50Cdc37 was assessed 
by Western blotting using phospho-specific antibody (Figure 1B–D). Attempts to verify pSer226 of 
Hsp90β failed due to the lack of specificity of commercially available antibodies against pSer226.  
The thermodynamic profiles of the complex formation between p50Cdc37 and Hsp90β proteins, and 
the effect of phosphorylation by CK2 were determined by direct binding studies using ITC (Figure 2A). 
With dissociation constants between 1.1 and 1.9 µM no significant differences in binding affinities were 
observed for the interaction of the different Hsp90 proteins with p50Cdc37. Only the N-terminal domain 
of Hsp90 displayed a slightly decreased binding potential (Kd = 4.4 µM). The Kd values are similar to 
the reported dissociation constant of 1.5 µM for the interaction of yeast Hsp82 with human p50Cdc37 [30]. 
Notably, phosphorylation of Hsp90 or p50Cdc37 did not appear to impact complex formation; the 
thermodynamic signatures were similar for phosphorylated and unphosphorylated proteins (Figure 2B). 
Complex formation is characterized by favourable enthalpy and unfavourable entropy contributions, 
indicative of substantial conformational changes in one or both proteins upon complex formation. The 
deletion mutant displayed an increase in both enthalpy and entropy, and the N-terminal domain appeared 
to interact with p50Cdc37 through a more favourable change in entropy, albeit at the expense of a 
significantly reduced enthalpy. These data suggest the involvement of regions beyond the N-terminal 
domain that undergo structural rearrangements upon complex formation.  
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Figure 1. In vitro reconstitution of the human full-length Hsp90β:p50Cdc37 complex and 
phosphorylation by CK2α. (A) Elution profiles and corresponding SDS-PAGE for analytical 
gel filtration experiments showing complex formation (blue) upon incubation of free Hsp90β 
(red) with free p50Cdc37 (green). (B) Coomassie-stained SDS-PAGE and Western blot analysis 
of purified Hsp90β in the presence and absence of CK2α and ATP using anti-Hsp90β (pSer255); 
(C) Coomassie-stained SDS-PAGE and Western blot analysis of purified p50Cdc37 in the 
presence and absence of CK2α and ATP using anti-p50Cdc37 (pSer13); (D) Phosphorylation 
states of Ser255 in Hsp90β upon phosphorylation by CK2α and dephosphorylation by 
alkaline phosphatase (AP). 
2.2. Effect of Phosphorylation on the Interaction of Hsp90β with Nucleotides and Inhibitors 
The influence of phosphorylation by CK2 on the binding potential of nucleotides and small molecule 
inhibitors was evaluated in a series of ITC experiments (Figure 3). Interaction with ADP was similar for 
unphosphorylated and phosphorylated Hsp90 and ΔHsp90 with Kd values between 9 and 13 µM, but 
significant changes were observed for ATP and AMP-PNP. The full-length protein interacted equally 
well with ADP and ATP, irrespective of its phosphorylation state, whereas deletion of the charged linker 
reduced the binding potential for ATP significantly (Kd = 43 µM). With Kd values of 84 and 85 µM, 
AMP-PNP was a relatively weak binder of ΔHsp90 and the full-length protein, and phosphorylation 
further reduced its binding potential (Kd > 500 µM). Similarly, the potent ATP site-directed inhibitor 
NVP-AUY922 interacted tightly with ΔHsp90β and unphosphorylated full-length protein (Kd < 10 nM), 
but phosphorylation appeared to reduce the binding affinity (Kd = 0.1 µM). The data suggest that 
phosphorylation of the charged linker region influences the interaction of Hsp90 with ATP site-directed 
ligands. The dissociation constants determined here for unphosphorylated human Hsp90β correlate well 
with previously reported values for Hsp90 proteins, with the exception of ATP (Table 1). Conspicuously, 
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the recently proposed Hsp90 inhibitors gedunin and H2-GMZ failed to display binding potential towards 
Hsp90β (Figure 3). None of the nucleotides and inhibitors interacted with p50Cdc37 (data not shown). 
 
Figure 2. Influence of phosphorylation by CK2 on the thermodynamics of Hsp90β-p50Cdc37 
complex formation. (A) Isothermal titration calorimetry (ITC) experiments of the  
Hsp90β-p50Cdc37 complex formation using unphosphorylated and phosphorylated proteins. 
The last two graphs show the interactions of Hsp90 without the acidic loop (ΔHsp90) and of 
the N-terminal domain (N-Hsp90); (B) Thermodynamic signatures of the protein–protein 
interactions (PPI). 
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Figure 3. Interaction of Hsp90β proteins with nucleotides and reported inhibitors determined by ITC. Shown are the results of titrations 
experiments for small molecule ligands with ΔHsp90β (A); full-length Hsp90β (B); and CK2-phosphorylated Hsp90β (C).
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Table 1. Dissociation constants determined by ITC and comparison with reported values. 
Binding Partner/Ligand Hsp90 Observed Kd (µM) Reported Kd (µM) Reference 
p50Cdc37 
yHsp82-FL n/d 1.46 [30] 
hΔHsp90β 1.1 n/a  
hHsp90β-N 4.4 n/a  
hHsp90β-FL 1.2 n/a  
h(p)Hsp90β-FL 1.7 n/a  
(p)p50Cdc37 
hHsp90β-FL 5.1 n/a  
h(p)Hsp90β-FL 8.6 n/a  
ADP 
hΔHsp90β 11 n/a  
hHsp90β-FL 8.9 7.2 [31] 
h(p)Hsp90β-FL 13 n/a  
ATP 
hΔHsp90β 43 n/a  
hHsp90β-FL 4.6 240 [31] 
h(p)Hsp90β-FL 11 n/a  
AMP-PNP 
hΔHsp90β 84 n/a  
hHsp90β-FL 85 148 [31] 
h(p)Hsp90β-FL 590 n/a  
NVP-AUY922 
hΔHsp90β <0.01 n/a  
hHsp90β-FL <0.01 0.0017 [32] 
h(p)Hsp90β-FL 0.1 n/a  
17-DMAG 
hHsp90β-FL n/d 0.35 [33] 
hΔHsp90β 0.79 n/a  
Radicicol 
yHsp82-FL n/d 0.019 [34] 
hΔHsp90β <0.01 n/a  
2.3. Evaluation of Small Molecules as PPI Inhibitors of the Hsp90β-p50Cdc37 Complex 
Next, we developed a robust ELISA assay using immobilized GST-p50Cdc37 to determine the  
effect of nucleotides and inhibitors on complex formation with Hsp90β using unphosphorylated and 
CK2-phosphorylated proteins (Figure 4 and Table 2). Among the compounds tested, only ADP displayed 
appreciable disruptive potential against the unphosphorylated complex with IC50 values between 400 
and 500 µM. The inhibitory activity of ADP slightly increased upon phosphorylation of either Hsp90 or 
p50Cdc37 (IC50 = 220–270 µM), while phosphorylation of both proteins significantly increased sensitivity 
of the complex towards ADP (IC50 = 32 µM). ATP was largely ineffective against the unphosphorylated 
complex (IC50 > 1 mM), while the phosphorylated complex was inhibited by ATP with an IC50 value of 
230 µM. AMP-PNP and NVP-AUY922, along with gedunin and H2-GMZ, did not show appreciable 
inhibitory activity against the unphosphorylated or phosphorylated complex. These results indicate that 
ADP is a remarkably potent and differential inhibitor of the interaction between phosphorylated Hsp90β 
and p50Cdc37. 
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Figure 4. Effect of nucleotides and inhibitors on the Hsp90β-p50Cdc37 complex as determined 
by ELISA. (A) Dose-response experiments for the complex formation between immobilized 
GST-p50Cdc37 and Hsp90β (unphosphorylated or phosphorylated) in the presence of ADP, 
ATP, AMP-PNP, NVP-AUY922, gedunin, or H2-GMZ, as indicated; (B) Replot of (A) to 
compare the effect of phosphorylation on the stability of the complex. The Hsp90-(p)p50Cdc37 
complex was probed only against ADP and ATP but not against inhibitors. IC50 values are 
shown in Table 2. 
Table 2. Disruptive potential of small molecules against Hsp90β-p50Cdc37 complexes 
determined by ELISA. 
Complex 
IC50 (µM) 
ADP ATP AMP-PNP H2-GMZ H2-GMZ Gedunin NVP 
Hsp90-p50Cdc37 500 ± 94 >1000 >1000 >1000 >1000 >1000 >1000 
(p)Hsp90-p50Cdc37 220 ± 24 450 ± 150 >1000 >1000 >1000 >1000 >1000 
Hsp90-(p)p50Cdc37 270 ± 35 >1000 n/d n/d n/d n/d n/d 
(p)Hsp90-(p)p50Cdc37 32 ± 5.6 230 ± 40 >1000 >1000 >1000 >1000 >1000 
ΔHsp90-p50Cdc37 400 ± 81 >1000 >1000 >1000 >1000 >1000 >1000 
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2.4. ADP Exerts Inhibitory Activity through Binding to the ATP Site in the N-Terminal Hsp90 Domain 
To assess if the inhibitory activity of ADP is a result of binding to the ATP site, we performed 
competition experiments by GST-pull down and ELISA using radicicol as a representative ATPase 
inhibitor of Hsp90, in parallel with gedunin and H2-GMZ. Under these conditions, only ADP inhibited 
formation of the complex. The presence of radicicol completely protected the complex from ADP, 
indicating competition for binding to the same site (Figure 5A). As expected from the ITC experiments, 
gedunin and H2-GMZ were ineffective. ELISA assays confirmed that ATP site-directed Hsp90 inhibitors 
ameliorated the effect of ADP for both ΔHsp90β and ΔHsp90α (Figure 5B,C). Finally, ITC experiments 
using the N-terminal domain of Hsp90β revealed that its interaction with p50Cdc37 was abolished in the 
presence of 5 mM ADP (Figure 5D). Combined, the data suggest that the PPI inhibitory activity of ADP 
is a result of binding to the ATP site in the N-terminal domain of Hsp90. 
2.5. Possible Structural Basis for the PPI Inhibitory Activity of ADP  
To explore potential structural changes in Hsp90 uniquely induced by ADP, we compared a set of 
crystal structures available for human N-terminal Hsp90α (unliganded: PDB 3T0H [35], ADP: PDB 
1BYQ [36], ATP: PDB 3T0Z [35], AMP-PNP: PDB 3T1K [35], 17-DMAG: PDB 1OSF [37],  
NVP-AUY922: PDB 2VCI [38]). Substantial structural changes occur in Hsp90 upon ligand binding, 
particularly near residues 100–127, with root mean square deviations (r.m.s.d.) up to 10 Å (Figure 6A). 
The only crystal structure available for the Hsp90-p50Cdc37 complex is that of yeast N-terminal Hsp82, 
void of nucleotides, with a C-terminal construct of human p50Cdc37 [30]. Superposition of this complex 
with the aforementioned structures of liganded N-terminal Hsp90 illustrates that, among the structurally 
variable regions, only helix 114–124 directly interacts with p50Cdc37. This helix adopts distinctly different 
conformations, depending on the type of ligand bound to the ATP site (Figure 6B). The nucleotide-liganded 
states share a similar helix conformation which differs significantly from the conformation adopted upon 
interaction with p50Cdc37. It is conceivable that stabilization of the helix conformation in the nucleotide 
liganded states negatively impacts the interaction with p50Cdc37. The structural basis for the high inhibitory 
activity of ADP relative to ATP or AMP-PNP is less obvious and will require crystal structures of the 
full-length human Hsp90-p50Cdc37 complex liganded with nucleotides or ATPase inhibitors. For the 
known yeast Hsp90-p50Cdc37 structure, the protein–protein interface in the immediate vicinity of the ATP 
site suggests that the Arg167 side chain of p50Cdc37 may establish a salt bridge with the terminal phosphate 
group of ATP or AMP-PNP, but not with ADP. The inability of ADP to interact with this arginine residue 
may explain the differential inhibitory activity of ADP versus ATP. 
3. Experimental Section 
3.1. Materials 
All reagents were purchased from Sigma-Aldrich unless otherwise noted. Radicicol and gedunin were 
purchased from Tocris Bioscience. NVP-AUY922 and 17-DMAG were purchased from Selleck Chemicals. 
H2-GMZ was synthesized as previously described [27]. Stock solutions were freshly prepared at 100 mM 
concentration in water (nucleotides) or in 100% DMSO (inhibitors) and were stored in 0.1 mL  
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aliquots at −80 °C. Protein concentration was determined by A280 molar absorbance using a Nanodrop 
ND-1000 spectrophotometer. 
 
Figure 5. The PPI inhibitory activity of ADP proceeds through binding to the ATP site of 
Hsp90. (A) SDS-PAGE of GST pull-down experiments for ΔHsp90β interaction with  
GST-p50Cdc37. The two proteins were incubated with 1 mM nucleotide or 0.1 mM inhibitor 
for 15 min, loaded onto a GST-affinity column, and eluted with reduced glutathione. The upper 
gels show elution of a stable complex in the presence of inhibitors or ATP, but the presence 
of ADP caused disruption of the complex. The bottom gel shows the result of a competition 
experiment in which the presence of 0.1 mM radicicol protected the complex from ADP, 
whereas gedunin and H2-GMZ had no effect. L = load, C = control (no ligand), Rad = radicicol, 
Ged = gedunin, H2 = H2-GMZ; (B,C) Competition experiments for the interaction of 
ΔHsp90β (B) or ΔHsp90α (C) with p50Cdc37 in the presence of 1 mM ADP and 0.25 mM 
inhibitors (0.1 mM for gedunin) determined by ELISA. Only ATP site-directed inhibitors 
protected the complex from ADP; (D) Binding isotherms for the interaction of the N-terminal 
domain of Hsp90β with p50Cdc37 in the absence and presence of ADP. 
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Figure 6. ADP-induced structural changes in Hsp90 may impact complex formation with 
p50Cdc37. (A) Root mean square deviation (r.m.s.d.) analysis of the N-terminal domain of 
human Hsp90α in the ligand-free state (3T0H) against the liganded states with ADP (1BYQ), 
17-DMAG (1OSF), or NVP-AUY922 (2VCI). Residues 100-127 and, to a lesser extent, 
residues 55-75, undergo large structural changes upon ligand binding, corresponding to the 
blue and red highlighted regions of the yeast Hsp90:human p50Cdc37 complex (1US7) shown 
at the top of the graph. p50Cdc37 is shown in cyan; (B) Superposition of different liganded 
states of the N-terminal domain of Hsp90 show conformational changes that may impact the 
interaction with p50Cdc37. 
3.2. Cloning and Expression 
The gene encoding human full-length Hsp90β was subcloned from T47D cell line cDNA, and human 
full-length CK2α was subcloned from MCF7 cell line cDNA, both a kind gift from Dr. Jonathan Lancaster, 
Moffitt Cancer Center. The genes encoding the deletion mutants human Hsp90α (1-732 Δ226-283), 
human Hsp90β (1-724 Δ220-275), human N-terminal Hsp90β (1-219, denoted Hsp90β-N), and human 
full-length p50Cdc37 (residues 1-378) were synthesized by GeneArt AG with optimized codon usage for 
E. coli expression. The deleted sections in the two Hsp90 genes were each replaced by four glycine 
residues. Hsp90α and Hsp90β were subcloned into the pET28a vector (Novagen), and p50Cdc37 was 
subcloned into a modified pET28a vector containing a maltose-binding protein (MBP) solubility tag and 
a PreScission protease cleavage site using restriction enzymes BamHI and NotI (Fermentas) and T4 
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DNA ligase (Invitrogen) following the manufacturers’ instructions. BamHI was substituted with NdeI 
for full-length Hsp90β. p50Cdc37 was also subcloned into the pGEX6P-1 vector (GE Healthcare) using 
the same procedure as above to provide an N-terminal GST-tag for GST pull-down and ELISA experiments. 
The plasmids were transformed into E. coli BL21 Star (DE3) (Hsp90α and Hsp90β, Invitrogen), Tuner 
(DE3) (p50Cdc37 modified pET28a, Novagen), or BL21 (DE3) (p50Cdc37 pGEX6P-1, Stratagene) expression 
strains. Transformed cells were grown in LB broth at 37 °C until the OD600 reached 0.4, then the temperature 
was lowered to 16 °C, and cells were induced with 0.1 mM IPTG at OD600 = 0.5–0.7. Cultures were then 
grown for 20–24 h before harvesting by centrifugation (30 min at 30,000× g, 4 °C). 
3.3. Protein Purification 
Harvested cells containing overexpressed proteins were resuspended in 50 mM Tris buffer (pH 8.0 at 
4 °C) containing 300 mM NaCl, 10 mM imidazole, 0.1 mg·mL−1 lysosyme, and 0.01% Triton X-100 at 
4 °C for 2 h. After sonication and centrifugation (35 min at 35,000× g), the target proteins were purified 
by FPLC using a combination of nickel affinity, anion exchange, and size-exclusion chromatography, 
incorporating an additional step to cleave the His6-MBP-tag from p50Cdc37 and CK2α using PreScission 
protease. GST-tagged p50Cdc37 and GST alone (as a control for ELISA studies) were purified using 
glutathione sepharose and size exclusion chromatography by FPLC. Analytical size exclusion 
chromatography was performed with a Superdex200 10/300 GL column at room temperature using  
a flow rate of 0.3 mL/min. Samples contained 85 µM protein in 50 mM HEPES (pH 7.5), 50 mM KCl, 
5 mM MgCl2, and 1 mM DTT. Eluted protein was collected in 1 mL fractions and analyzed on 12% 
SDS-PAGE gels stained with Coomassie blue for visualization. 
3.4. GST Pull-Down 
GST pull-down experiments were carried out using 1 mL GST 4 FastFlow resin in 8 mL Flex columns 
(Kontes). All experiments were performed at room temperature by gravity flow. Loading and wash buffers 
contained 50 mM Tris pH 8, 50 mM KCl, 5 mM MgCl2, and 5% DMSO. The elution buffer contained 
an additional 10 mM reduced glutathione. Protein/compound mixtures containing equimolar amounts of 
each protein (25 μM), as well as 1 mM nucleotide and/or 0.25 mM compound (0.1 mM gedunin due to 
solubility issues), in a 1 mL total volume were incubated for 15 min at room temperature prior to loading. 
The resin was washed with 20 CV wash buffer, and samples were eluted with 2 CV elution buffer. Eluted 
protein was analysed on 12% SDS-PAGE stained with Coomassie blue for visualization. 
3.5. In Vitro Phosphorylation 
Phosphorylation of full-length Hsp90β and p50Cdc37 was performed using purified full-length CK2α. 
The reaction was carried out in a 2.5 mL volume containing 50 µM Hsp90β or p50Cdc37, 0.5 µM CK2α, 
0.5 mM ATP, 20 mM Tris (pH 7.5), 50 mM KCl, and 10 mM MgCl2, and was incubated for 1 h at  
30 °C. Samples were removed for analysis of phosphorylation status, and the proteins were re-buffered 
into 50 mM HEPES (pH 7.5), 150 mM NaCl, and 1 mM DTT (ELISA), or into 50 mM HEPES (pH 7.5) 
for ITC, using PD-10 gravity columns (GE Healthcare). Dephosphorylation was performed using  
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2.5 units of FastAP (alkaline phosphatase from Thermo Scientific) in buffer containing 10 mM Tris  
(pH 8.0 at 37 °C), 5 mM MgCl2, 100 mM KCl, 0.02% Triton-X 100, and 0.5 mg/mL BSA for 1 h at 37 °C.  
3.6. SDS-PAGE and Western Blot Analysis 
Samples were run on 12% SDS-PAGE gels at 120 V and 4 °C for 1.5 h. The gels were then either 
stained with Coomassie Blue at room temperature or transferred to a PVDF membrane in a wet-transfer 
Mini Trans-Blot Cell (Bio-Rad) following the manufacturer’s instructions. The membrane was blocked 
with 5% skim milk in 1× TBS-T (50 mM Tris pH 8, 150 mM NaCl, 0.1% (v/v) Tween-20) and rinsed 
with 1× TBS-T. The membrane was incubated overnight at 4 °C with anti-p50Cdc37 phosho-pS13 rabbit 
mAb (Epitomics, diluted to 0.04 μg/mL) or anti-Hsp90β phospho-pS255 rabbit pAb (Abcam, diluted to 
2 µg/mL) in SuperBlock + 0.01% Tween-20 (Thermo Scientific, Rockford, IL, USA), and then incubated 
with anti-rabbit horseradish peroxidase (HRP)-conjugated IgG secondary antibody (Cell Signaling 
Technology) for 2 h at room temperature. Western blots were developed using HyGLO Quick Spray 
HRP substrate and exposed on HyBlot CL autoradiography film (Denville Scientific). 
3.7. ELISA Microtiter Plate Assay 
Purified GST-p50Cdc37 (4 µM) or control (purified GST alone, 4 µM) was added to glutathione-coated 
96-well plates (Pierce) in 100 μL protein buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 10 mM MgCl2, 
0.05% Tween-20, and 0.1% BSA) and incubated for 1 h at room temperature (triplicate wells per 
sample). Wells were washed three times with 1× HBS-T (50 mM HEPES pH 7.5, 150 mM NaCl, 0.05% 
Tween-20) and blocked with 250 μL 5% BSA (w/v) and 10 mM MgCl2 in 1× HBS-T for 1 h at room 
temperature before washing again three times with 1× HBS-T. Purified His6-Hsp90 protein (4 μM) was 
pre-incubated in protein buffer with nucleotides and/or small molecule inhibitors in the presence of 5% 
DMSO for 30 min at room temperature (the presence of DMSO was not found to significantly affect the 
protein–protein interactions). The mixtures were then added to the wells (100 μL per well, in triplicates) 
and incubated for 1 h at room temperature before washing. The wells were incubated with anti-His6-tag 
mAb (1 mg/mL stock, Abcam), diluted 1:2000 in antibody buffer (50 mM HEPES pH 7.5, 150 mM 
NaCl, 10 mM MgCl2, 0.05% Tween-20, and 1% BSA) for 1 h, followed by secondary antibody (horse 
anti-mouse HRP-conjugated IgG, Cell Signaling Technology), diluted 1:5000 in antibody buffer, for 1.5 h 
at room temperature. After washing three times with 1× HBS-T and two times with 1× HBS, 200 μL 
HRP substrate (SigmaFast OPD) was added per well. The plates were incubated at room temperature, 
and the absorbance was read at 450 nm after 15 min and 30 min using a SpectraMax 340 PC plate reader 
(Molecular Devices). For dose-response measurements, absorption values were corrected for unspecific 
binding of Hsp90 to immobilized GST, and the raw data were fit to equation (1), where f(I) is the fraction 
of complex remaining, [I] is the concentration of the inhibitor, IC50 is the half maximal inhibitory 
concentration against Hsp90-p50Cdc37 complex formation, n is the Hill slope coefficient, min is the signal 
remaining at high inhibitor concentrations and max is the signal of the uninhibited complex. Corrected 
absorption values (ΔOD) for the uninhibited Hsp90-p50Cdc37 complex (unphosphorylated and 
phosphorylated) were in the range of 0.4–1.0. Data were expressed relative to the respective max value 
of Equation (1). 
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3.8. Isothermal Titration Calorimetry (ITC) 
Binding of p50Cdc37 and small molecules to Hsp90 was analyzed using a MicroCal iTC200 titration 
calorimeter (GE Healthcare). Compounds or p50Cdc37 were titrated into a solution of Hsp90 using the 
following concentrations: p50Cdc37 (200 µM) into Hsp90 (20 µM), nucleotides (600 µM) into Hsp90  
(30 µM), inhibitors (300 µM) into Hsp90 (30 µM). Titrations of compounds into p50Cdc37 were 
performed with similar compound/protein ratios. All experiments were conducted in 50 mM HEPES  
pH 7.5, 10 mM MgCl2 at 30 °C. For titration of inhibitors, the buffer contained 5% DMSO. Typically, 
an initial 0.5 µL injection was followed by 19 injections of 2.2 µL of syringe solution (compound or 
p50Cdc37) into a 200 µL protein solution of Hsp90 constantly stirred at 1000 rpm, and data were recorded 
for 180 s between injections. Generation of heat due to dilution was determined in separate experiments 
by diluting protein into buffer and subtracting these as blank values for each injection. Corrected heat 
values were fitted using a nonlinear least squares curve-fitting algorithm (Microcal Origin 7.0) to obtain 
the stoichiometry (n), binding constants (Ka, Kd), and change in enthalpy for each enzyme-ligand 
interaction (ΔH). 
4. Conclusions 
Targeted disruption of the Hsp90-p50Cdc37 complex by PPI inhibitors has emerged as an alternative 
strategy to treat diseases characterized by aberrant Hsp90 activity. However, reported PPI inhibitors  
of Hsp90-p50Cdc37 such as gedunin and H2-GMZ have not been validated by direct binding studies or 
co-crystal structures. In this study, we applied three methods to comprehensively evaluate the effect of 
selected Hsp90 inhibitors and nucleotides on complex formation, and the influence of phosphorylation 
by CK2. We found that ADP is an effective inhibitor of the phosphorylated complex with an IC50 value 
of 32 µM, while ATPase and PPI inhibitors of Hsp90 were inactive. Notably, previous studies using 
yeast Hsp90 showed that the ATPase inhibitor geldanamycin did not influence complex formation with 
human p50Cdc37 or yeast Cdc37 protein [39]. The data suggest that phosphorylation by CK2 primes the 
complex for dissociation upon interaction with ADP, or upon hydrolysis of bound ATP (Figure 7). Hsp90 
harbours multiple phosphorylation sites for CK2 while p50Cdc37 is phosphorylated at a single site, but 
the structural consequences of phosphorylation for the complex are unknown. Current structural 
information is limited to the complex of the N-terminal domain of yeast Hsp82 with the C-terminal 
domain of p50Cdc37 [30]. Our data indicate that regions beyond the N-terminal domain of Hsp90 participate 
and influence the complex, possibly the charged linker which harbours two CK2 phosphorylation sites. 
Hsp90 has been proposed as an ATP sensor, regulating the stability of client proteins in response to the 
ATP/ADP ratio [40]. The differential activity of ADP over ATP (10-fold difference in IC50 values) 
suggests that a drop in the ATP/ADP ratio causes dissociation of the complex, probably followed by the 
degradation of client proteins [10].  
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Figure 7. Graphical illustration of the major findings of this work. 
Our findings conflict previous reports from GST pull-down experiments, in which ADP did not  
exert inhibitory activity against the Hsp90β-p50Cdc37 complex [26]. However, 1:1 stoichiometry of both 
partner proteins was not achieved in these studies, suggesting that the proteins used or the experimental 
conditions applied were suboptimal for the complete in vitro reconstitution of the complex. Gedunin and 
H2-GMZ were proposed as inhibitors of the Hsp90-p50Cdc37 complex based on co-immunoprecipitation 
experiments with SkBr3 whole cell lysates and proteolytic fingerprinting using rabbit reticulocyte  
lysate [29]. It is possible that the effects observed in these studies were caused by Hsp90 partner proteins 
other than p50Cdc37 or by post-translational modifications other than phosphorylation by CK2. The approach 
applied herein provides robust assays for the biochemical evaluation of potential effectors of the  
Hsp90-p50Cdc37 complex, such as phosphorylation by a kinase or the interaction with small molecules. 
Therefore, the results from this work may serve drug development campaigns towards the identification 
and validation of compounds with potential as PPI inhibitors of Hsp90. 
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